Research report · Public share

中國生物製藥

HK · 01177 · 2026-10-31 · Full research
Cautiously bullish
Investment opportunity不含授權的創新藥收入78.1億元(+29.2%、佔40.2%)已成長主引擎,2026年內連簽賽諾菲/AZ/Cipla/STADA四單對外授權(可重複性待跨年驗證),而現價4.82港元(2026-10-30凍結錨)對應FY2026E經調整本益比約13.7-15.5倍(本報告中值56億元 vs 中金49.21億元)、股價淨值比近1年約4%分位;折價含授權脈衝性、少數股東分潤與南向流出的真實成分,18個月內AASLD、健保雙目錄、TQB2102獲批、AZ首付款確認與天晴65%併表構成可驗證修復路徑,基準公允5.4-5.9港元(較現價+12%~+22%),但熊案
How was this report? Leave anonymous feedback.
This report was generated automatically by Loyan AI. For research reference only — not investment advice.
Want a research assistant that never forgets and challenges its own views?
Sign in to add this research to your library, or register for free to get started.
Sign in / register free
中國生物製藥 · Full research — Loyan AI Research Partner